REVELATION BIOSCIENCES, INC. (REVB): Results of Operations and Financial Condition
REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-st
How this was made
The 30-second read
Why it matters
The most actionable items are the updated cash balance, cash burn trajectory, and the company’s stated funding runway through Q1 2027, which can influence expectations for financing and trial execution risk.
Market read
Investors get a fresh runway estimate and updated operating loss/cash burn, while clinical progress is framed as start-up activities with enrollment targeted by year-end.
What to watch
The press release highlights warrant inducement proceeds and operating cash burn changes, but does not quantify enrollment pace or upcoming cash needs beyond the runway statement, which may drive volatility.
Background
This is an SEC 8-K with Exhibit 99.1 reporting financial results for the three and six months ended June 30, 2026, plus corporate updates on Gemini Phase 2/3 AKI start-up activities.
Ticker impact
Revelation reported cash of $11.5M at June 30, 2026 and said it funds operations through Q1 2027, alongside Phase 2/3 AKI start-up progress.
Likely modest, two-sided reaction: supportive for runway clarity, but limited upside without enrollment/timeline specifics.
The filing provides concrete balance-sheet runway and operating cash burn, but does not disclose new clinical efficacy data or a definitive enrollment milestone beyond “starting enrollment by year-end.”
Market effects
Adds another datapoint on funding runway and execution risk for clinical-stage biotech, particularly inflammation and kidney disease programs.
Primarily US small-cap biotech sentiment; limited direct regional spillover.
Low, as the disclosure is company-specific and not tied to global regulatory or macro events.
Counterpoint
Runway through Q1 2027 plus continued trial start-up could reduce immediate financing fears, making the stock less fragile than cash-only headlines suggest.
Key entities
- issuerRevelation Biosciences, Inc.
Clinical-stage life sciences company developing Gemini (TLR4 agonist) across AKI, CKD, burn infection, and post-surgical infection indications.
- product_candidateGemini (PHAD, TLR4 agonist)
Proprietary formulation being evaluated in Phase 2/3 AKI (GEM-AKI) and other programs.
- program_updateAcute Kidney Injury Advisory Board
Formed for upcoming Phase 2/3 AKI trial and expanded, supporting trial start-up activities.
